Dacarbazine

Hemopoietic Depression; Hepatic Necrosis Risk

Should be administered under supervision of a qualified physician experience in the use of cancer chemotherapy.

  • Hemopoietic depression is the most common toxicity
  • Hepatic Necrosis has been reported
  • Carcinogen, Teratogen based on animal studies
  • Assessment of Benefit/Risk ratio should be considered in each patient

Monitoring data

  • Careful monitoring of red blood cells, white blood cells and platelet levels.

Package inserts

Additional information

Updated: July 2024